In:
Cancer, Wiley, Vol. 124, No. 7 ( 2018-04), p. 1449-1454
Abstract:
Dasatinib produces high 18 F‐fluorodeoxyglucose‐positron emission tomography response rates in tyrosine kinase inhibitor‐naive patients with gastrointestinal stromal tumors. Dasatinib may be received by patients who have specific mutations and as an additional line of treatment to increase overall survival.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1